Eltrombopag Trial for Low-Risk MDS and CMML
Phase 2
25
about 4.5 years
18+
1 site in OH
What this study is about
This trial is testing if a treatment called eltrombopag can improve blood cell counts in people with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) who have TET2 gene mutations. The goal is to see how the TET2 gene changes over time, and to evaluate if this treatment is effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Eltrombopag (EPAG)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
eltrombopag
oral (Oral Tablet)
Primary: Response Rate as assessed by hematologic response
Secondary: Progression Free Survival